Claire Dickson - Haleon Plc Chief Officer
| HLN Stock | USD 9.55 0.07 0.74% |
Executive
Claire Dickson is Chief Officer of Haleon plc
| Address | The Heights, Weybridge, United Kingdom, KT13 0NY |
| Phone | 44 1932 822000 |
| Web | https://www.haleon.com |
Haleon Plc Management Efficiency
The company has Return on Asset of 0.0445 % which means that on every $100 spent on assets, it made $0.0445 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0682 %, implying that it generated $0.0682 on every 100 dollars invested. Haleon Plc's management efficiency ratios could be used to measure how well Haleon Plc manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to drop to 0.12. In addition to that, Return On Capital Employed is likely to drop to 0.04. At this time, Haleon Plc's Non Current Assets Total are very stable compared to the past year. As of the 22nd of November 2024, Non Currrent Assets Other is likely to grow to about 435.8 M, while Total Assets are likely to drop about 27.7 B.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jeannette Astorga | Zoetis Inc | 49 | |
| Yoshihiro Nakagawa | Takeda Pharmaceutical Co | 64 | |
| Philippe Martin | Viatris | 49 | |
| Tove Bolken | SIGA Technologies | N/A | |
| Tiffany MBA | Esperion Therapeutics | N/A | |
| Eric Benevich | Neurocrine Biosciences | 59 | |
| Sauri Gudlavalleti | Dr Reddys Laboratories | 42 | |
| Kathleen Fitzpatrick | Bausch Health Companies | N/A | |
| Robert Burrows | Emergent Biosolutions | N/A | |
| Christopher OReilly | Takeda Pharmaceutical Co | N/A | |
| YUGANDHAR PUVVALA | Dr Reddys Laboratories | 48 | |
| Dimitri Grigoriadis | Neurocrine Biosciences | 66 | |
| Ramkumar Rayapureddy | Viatris | N/A | |
| Vivek Mittal | Dr Reddys Laboratories | N/A | |
| Jayanth Sridhar | Dr Reddys Laboratories | 53 | |
| Matthew Shields | Teva Pharma Industries | 50 | |
| Amanda Morgan | Lantheus Holdings | N/A | |
| JeanJacques Charhon | Bausch Health Companies | 59 | |
| Paul Campbell | Viatris | 57 | |
| Jane Sorensen | Neurocrine Biosciences | N/A | |
| Matthew Abernethy | Neurocrine Biosciences | 44 | |
Management Performance
| Return On Equity | 0.0682 | ||||
| Return On Asset | 0.0445 |
Haleon plc Leadership Team
Elected by the shareholders, the Haleon Plc's board of directors comprises two types of representatives: Haleon Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Haleon. The board's role is to monitor Haleon Plc's management team and ensure that shareholders' interests are well served. Haleon Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Haleon Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Keith Choy, President Pacific | ||
| Tamara Rogers, Chief Officer | ||
| Lisa Paley, President America | ||
| Adrian Morris, General Counsel | ||
| Brian McNamara, CEO Director | ||
| Bjarne Tellmann, General Counsel | ||
| Claire Dickson, Chief Officer | ||
| Bart Derde, Head Chain | ||
| Franck Riot, Chief Officer | ||
| Bjorn Timelin, Head Strategy | ||
| Tobias Hestler, Executive Officer | ||
| Amy Landucci, Head Technology | ||
| Namrata Patel, Chief Officer | ||
| Line Decker, Chief Officer | ||
| Jooyong Lee, Head CEO | ||
| Dawn Allen, CFO Director | ||
| Mairead Nayager, Chief Officer | ||
| Teri Lyng, Head Sustainability | ||
| Sonya Ghobrial, Head Relations | ||
| Ed Petter, Chief Officer | ||
| Filippo Lanzi, President LatAm |
Haleon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Haleon Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0682 | ||||
| Return On Asset | 0.0445 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 52.7 B | ||||
| Shares Outstanding | 4.52 B | ||||
| Shares Owned By Insiders | 4.37 % | ||||
| Shares Owned By Institutions | 11.50 % | ||||
| Number Of Shares Shorted | 7.91 M | ||||
| Price To Earning | 18.06 X |
Pair Trading with Haleon Plc
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Haleon Plc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Haleon Plc will appreciate offsetting losses from the drop in the long position's value.Moving against Haleon Stock
| 0.66 | CRNX | Crinetics Pharmaceuticals | PairCorr |
| 0.65 | AMLX | Amylyx Pharmaceuticals | PairCorr |
| 0.57 | PRAX | Praxis Precision Med | PairCorr |
| 0.55 | ALVO | Alvotech | PairCorr |
| 0.52 | AKRO | Akero Therapeutics | PairCorr |
The ability to find closely correlated positions to Haleon Plc could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Haleon Plc when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Haleon Plc - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Haleon plc to buy it.
The correlation of Haleon Plc is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Haleon Plc moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Haleon plc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Haleon Plc can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haleon plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Haleon Stock, please use our How to Invest in Haleon Plc guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haleon Plc. If investors know Haleon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haleon Plc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.348 | Dividend Share 0.062 | Earnings Share 0.34 | Revenue Per Share 2.446 | Quarterly Revenue Growth (0.01) |
The market value of Haleon plc is measured differently than its book value, which is the value of Haleon that is recorded on the company's balance sheet. Investors also form their own opinion of Haleon Plc's value that differs from its market value or its book value, called intrinsic value, which is Haleon Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haleon Plc's market value can be influenced by many factors that don't directly affect Haleon Plc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haleon Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Haleon Plc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haleon Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.